We discuss the sensitivity terminology of cardiac troponin assays and its dependence on the selection of the reference population. In addition, the need for reasonable censoring of clinical laboratory test results is contrasted with potential loss of valuable clinical information.
The discussion about the terminology of cardiac troponin (cTn) assays has been going on since the introduction of the first so-called high-sensitivity cTn assay and has increased in intensity with the recent approval by the US Food and Drug Agency of an assay that has been for last several years labeled high sensitivity outside the United States. Some laboratorians expressed their surprise that in contrast to other countries, this assay will not be deemed highly sensitive in the United States. However, this contradiction is not as surprising as it may seem and results partly from the confusing terminology of cTn assays and, to some extent, from various levels of necessary data censoring.
The definition of high-sensitivity cTn assays is problematic, and labeling of cTn assays as contemporary sensitive and high sensitivity is potentially misleading. Moreover, such a labeling is unnecessary and is likely to change as time progresses. What seemed sensitive a decade ago is barely contemporary nowadays. And a decade from now, performance of the current "ultrasensitive" assays may become the new sensitivity standard.
High-sensitivity cTn assays, as defined today, should have coefficient of variation (CV) ≤ 10% at the 99th percentile of cTn concentrations seen in healthy individuals.
In addition, the measured concentration should exceed the limit of detection (LoD) in at least 50% (ideally 95%) of healthy subjects [1] . It is unclear why 50%, or why ideally 95%, when 100% would appear the natural target of a high-sensitivity assay. Perhaps to leave room for the socalled ultrasensitive assays.? These assays have already achieved the goal of quantitating cTn in all healthy individuals [2, 3] and even exceeded this goal by being able to assess small variations in cTn levels caused by exercise stress testing [4] or detect short-and long-term biological variations [5] .
Because the performance of cTn assays is not linked to a set of internationally acceptable standards but to their performance in apparently healthy individuals, classification of a cTn assay depends heavily on the selection of the reference population. cTn levels are higher in males compared to females but that is not an issue because typical reference cohorts include equal representation of both sexes. Moreover, cTn levels in the reference group differ with age, ethnic background and acceptable comorbidities. So not too surprisingly, if we mechanically adhere to the criteria set forth above, the same assay may end up being labeled high sensitivity on one continent and not as high sensitivity on another. Without detailed knowledge of the makeup of the reference group, we cannot decide which labeling is or is not correct. In fact, either labeling may be fine.
Even more paradoxically, if we apply these criteria, a cTn assay may fulfill criteria of high sensitivity in males but not in females. It could be high sensitivity in apparently healthy sexagenarians but not in younger subjects. This contradiction is not as far-fetched and as artificial as it may seem because many clinicians and laboratorians nowadays advocate the use of sex-and age-specific reference ranges [6] .
Given the importance of cTn for timely diagnosis of acute myocardial infarction (AMI), emotions around cTn testing have always run high. Because the sensitivity of the first cTn assays was very low, with LoDs of 100-500 ng/L, only large AMIs were diagnosed using cTn assays, whereas small and medium AMIs remained undetected. Not surprisingly, cTn was initially viewed by many as a dichotomous *Corresponding author: Petr Jarolim, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, E-mail: pjarolim@bwh.harvard.edu variable. Detectable, i.e. "positive", was bad, confirming the diagnosis of AMI, whereas nondetectable, i.e. "negative" or "normal", did not generate much attention.
Although the increasing precision of novel cTn assays kept shifting the "positive/negative" cutoff lower and lower, the black and white interpretation remained engrained in clinicians' minds for a long time. Nevertheless, such dichotomous classification of troponin results has been gradually replaced by viewing cTn concentration as a continuous variable. We now use cTn assays to diagnose very small AMIs and understand that cTn elevations are associated with multiple acute and nonacute cardiac as well as noncardiac conditions [7, 8] . We interpret cTn levels based on the assay's negative and positive predictive values at various cTn concentrations and use even minor elevations in cTn levels as a powerful prognosticator of adverse events [9, 10] .
As mentioned in the beginning, the definition of assay sensitivity is related to data censoring. Censoring of test results per certain preestablished criteria inevitably leads to the loss of some information. Such information may be at times helpful and, under other circumstances, may not be helpful or can even be confusing. In the case of cTn assays, the loss of information due to data censoring has been emphasized by several groups [11] [12] [13] .
The fact that overzealous censoring of cTn data leads to a loss of diagnostic and prognostic information has been made abundantly obvious when laboratories were instructed not to report cTn results for concentrations for which the assay performed with CV > 10%. This practice negated the usual reporting of results with CV up to 20%, the value typically used as the limit of quantitation (LoQ). This type of data censoring is surviving in many laboratories and leads to the loss of valuable prognostic information. Moreover, such approach will make the transition to more sensitive assays seemingly dramatic as this change will be associated with many more measurable and reportable cTn concentrations.
It has been demonstrated multiple times that any troponin T (cTnT) concentration greater than LoD of the 4th generation cTnT assay, i.e. 10 ng/L, is strongly associated with adverse outcomes such as in the study of community dwelling individuals where it was associated with dramatically lower 8-year survival [14] . This valuable prognostic information is lost due to censoring of data with CV in the 10-20% range. Similarly, it has been repeatedly shown that there is a gradient of risk for adverse outcomes even in the so-called reference range, i.e. between the LoB and LoD [13] or LOD and the 99th percentile [3, 15] . This again would speak against unnecessary data censoring. However, suggestions have been made to take this approach even one step further, to eliminate data censoring altogether and to report all cTn results, even those below the limit of blank (LoB). I do not think this would be a valid approach. Reporting below LoB would have to be accompanied by reporting not only the result of the measurement itself but also the uncertainty or confidence intervals for each measurement. Reporting of uncertainty would have to also apply to the absolute or relative changes in cTn concentrations, a crucial concept in the rule-in/rule-out AMI algorithms.
This type of reporting may be scientifically more accurate but clinically unmanageable. Emergency room clinicians must make quick diagnostic and therapeutic decisions while considering multiple uncertainties surrounding each patient. Increasing this ambiguity by reporting the uncertainty the laboratories face when measuring any analyte would serve neither the clinicians nor the patients. Clinical laboratories are not doing particle physics where even a miniscule likelihood of detecting a signal, with a huge confidence interval, is an information worth reporting. Of course, if such a signal were detected, the measurement would be repeated multiple times until a reasonable level of certainty of distinguishing signal from noise is achieved.
Clinical laboratories do not have this luxury -they must report just one number and report it fast. And instead of reporting any result, they need to censor those results whose uncertainty is too high. Instead of reporting uncertainty of a measurement, laboratories can help clinicians by reporting properly established reference ranges and potentially age-and sex-specific diagnostic cutoffs, by calculating absolute or relative changes in cTn concentrations between individual time points, or even by normalizing these cTn changes and reporting them as a rate of change.
Performance characteristics of any test including cTn assays are essential and affect the way clinical laboratories report results, be it down to LoB, LoD or LoQ. The medium, high-sensitivity or ultrasensitive terminology appears helpful at the first sight as it seems to offer guidance for the use of these assays and for interpretation of test results. However, upon further consideration, its complete dependence on the reference population and on the allowable censoring restricts its universal applicability and makes it short-lived. Fortunately, discussions around this topic will become obsolete the moment we clinically implement the first assay capable of measuring cTn with CV < 20% in all subjects. Such assays are already available but are not yet ready for clinical prime time.
